Beta Bionics, Inc. (NASDAQ:BBNX) Given Consensus Recommendation of “Moderate Buy” by Analysts

Shares of Beta Bionics, Inc. (NASDAQ:BBNX) have been assigned a consensus rating of “Moderate Buy” from the eleven ratings firms that are covering the company, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation, six have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month target price among brokers that have covered the stock in the last year is $19.70.

Several research analysts have commented on the stock. The Goldman Sachs Group decreased their target price on shares of Beta Bionics from $19.00 to $17.00 and set a “buy” rating for the company in a research report on Wednesday, May 27th. Leerink Partners decreased their target price on shares of Beta Bionics from $25.00 to $24.00 and set an “outperform” rating for the company in a research report on Wednesday, April 22nd. Bank of America decreased their target price on shares of Beta Bionics from $23.00 to $11.00 and set a “neutral” rating for the company in a research report on Monday, May 18th. Stifel Nicolaus decreased their target price on shares of Beta Bionics from $22.00 to $20.00 and set a “buy” rating for the company in a research report on Wednesday, April 22nd. Finally, Weiss Ratings cut shares of Beta Bionics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, April 21st.

Insiders Place Their Bets

In other news, insider Mike Mensinger sold 4,378 shares of the stock in a transaction that occurred on Tuesday, June 2nd. The shares were sold at an average price of $12.61, for a total value of $55,206.58. Following the completion of the transaction, the insider directly owned 184,415 shares in the company, valued at $2,325,473.15. This trade represents a 2.32% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Christy Jones sold 2,811 shares of the stock in a transaction that occurred on Thursday, June 4th. The shares were sold at an average price of $14.00, for a total transaction of $39,354.00. Following the completion of the transaction, the director owned 27,400 shares of the company’s stock, valued at $383,600. This trade represents a 9.30% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 27,687 shares of company stock valued at $343,586. 5.30% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in BBNX. Vanguard Group Inc. boosted its holdings in shares of Beta Bionics by 213.5% in the third quarter. Vanguard Group Inc. now owns 2,216,185 shares of the company’s stock valued at $44,036,000 after acquiring an additional 1,509,217 shares in the last quarter. Healthcare of Ontario Pension Plan Trust Fund bought a new position in shares of Beta Bionics in the fourth quarter valued at approximately $40,437,000. Eversept Partners LP boosted its holdings in shares of Beta Bionics by 108.6% in the first quarter. Eversept Partners LP now owns 1,414,838 shares of the company’s stock valued at $14,177,000 after acquiring an additional 736,576 shares in the last quarter. 12 West Capital Management LP acquired a new stake in Beta Bionics during the fourth quarter valued at approximately $17,520,000. Finally, Bruce & Co. Inc. acquired a new stake in Beta Bionics during the first quarter valued at approximately $5,518,000.

Beta Bionics Stock Performance

NASDAQ BBNX opened at $13.88 on Friday. Beta Bionics has a 52 week low of $8.80 and a 52 week high of $32.71. The stock has a market cap of $618.49 million, a price-to-earnings ratio of -9.19 and a beta of 3.40. The company has a 50-day moving average price of $11.71 and a two-hundred day moving average price of $16.09.

Beta Bionics (NASDAQ:BBNX) last posted its earnings results on Tuesday, April 21st. The company reported ($0.49) EPS for the quarter, topping the consensus estimate of ($0.53) by $0.04. Beta Bionics had a negative net margin of 60.27% and a negative return on equity of 23.00%. The firm had revenue of $27.63 million during the quarter. As a group, equities research analysts expect that Beta Bionics will post -2.22 earnings per share for the current fiscal year.

About Beta Bionics

Beta Bionics, a clinical-stage medical device company headquartered in Boston, Massachusetts, is focused on revolutionizing the management of type 1 diabetes through automated insulin delivery solutions. The company’s flagship product, the iLet Bionic Pancreas system, is designed to simplify glycemic control by automatically adjusting insulin dosing in response to continuous glucose monitoring data. By integrating advanced algorithmic control with wearable infusion pumps, the iLet aims to reduce the daily burden of diabetes management and improve clinical outcomes for patients.

At the core of Beta Bionics’ offering is its proprietary bionic pancreas software, which can operate in both insulin-only and dual‐hormone modes.